Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITÄT BASEL maintains a portfolio with 9 pending office actions, primarily focused within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is distributed across 9 distinct examiners. This distribution suggests a broad engagement with the patent office, as the count of examiners equals the total of 9 pending office actions. Furthermore, these cases are spread across 8 distinct art units, reflecting a diverse range of technical subject matter within the specified technology area.
SAHAND, SANA is identified as the busiest examiner for the portfolio, currently handling 1 busiest examiner pending action. This figure indicates that no single examiner is overwhelmed by the university's filings, as the busiest individual manages only 1 of the pending office actions. For practitioners, this decentralized structure across 8 distinct art units may require coordinating with multiple specialized groups within the office. The parity between pending office actions and distinct examiners highlights a lack of examiner overlap in the current docket. This administrative variety suggests that prosecution outcomes may vary depending on the specific examiner and art unit assigned to each case.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 2 (22%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 5 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAHAND, SANA | 1 | 63.4% | +23.8% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| WALKER, OLIVIA | 1 | 35.7% | +75.0% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| PRAGANI, RAJAN | 1 | 53.3% | +70.0% |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 63d |
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | — |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | — |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 104d overdue |
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | — |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | — |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | — |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
| 17415735 | NA+/K+ ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1637 | 1 |
| 1644 | 1 |
| 3796 | 1 |
| 1641 | 1 |
| 1671 | 1 |
| 1614 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | — | §101§103§112 | Non-Final OA | — | Pending | Apr 10, 2025 |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | 63d | Pending | Sep 05, 2023 |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | 3796 | §102§103 | Non-Final OA | — | Pending | May 02, 2023 |
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Final Rejection | 110d overdue | Pending | Feb 14, 2023 |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | 1671 | §103§112Other | Final Rejection | — | Pending | Apr 28, 2022 |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 1614 | §103 | Final Rejection | 104d overdue | Pending | Jan 17, 2022 |
| 17415735 | NA+/K+ ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Jun 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial